CHP Merger — SPAC Merger (March 2022)
42 slides from CHP Merger's SPAC merger presentation, Mar 1, 2022
Slide 1: Investor Presentation March 2022
Exhibit 99.1 INVESTOR PRESENTATION March 2022 Accelerating MIS Spine Culture | Technology | Accessibility
Slide 2: Disclaimer and Confidentiality Notice
DISCLAIMER AND CONFIDENTIALITY NOTICE In this presentation, “Accelus”, the “Company”, “we”, “us” and “our” mean Integrity Implants Inc. d/b/a Accelus. All amounts are in U.S. dollars unless otherwise indicated. The information contained herein does not purport to contain all of the information about
Slide 3: Disclaimer and Confidentiality Notice (non-GAAP)
DISCLAIMER AND CONFIDENTIALITY NOTICE This presentation includes certain financial measures not presented in accordance with GAAP. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and asses
Slide 4: Investment Rationale
INVESTMENT RATIONALE Accelus provides a compelling opportunity for CHP Massive Market Positive Clinical Affordable, Opportunity Outcomes Accessible Solution Attractive Growth Profile, Leverage CHP’s Health High Gross Margins System Relationships Differentiated Platform Disrupting Minimally Invasive
Slide 5: Our Mission: Accelerating Minimally Invasive Spine Surgery
OUR MISSION: Accelerating Minimally Invasive Spine Surgery ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 5
Slide 6: Accelus at a Glance
ACCELUS AT A GLANCE Improving procedures and outcomes, creating favorable economics, and providing broad accessibility Transformational robotic solution, reducing procedural complexity and Clinically-impactful, data- Attractive busines accelerating growth driven, cost-effective, model with pull-thro
Slide 7: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY SPINAL FUSION MARKET SIZE OF ACCELUS’ CURRENT ADDRESSABLE MARKET • Large, established addressable market Pedicle Biologics • Demographics support continued market growth Screws and • Growing international spinal fusion market of $3.0 billion Rods $0.8B Other • Industry
Slide 8: Spinal Fusion Surgery Status Quo
SPINAL FUSION SURGERY STATUS QUO Opportunities to Address Substantial Unmet Clinical Needs MIS Procedures Remain Underpenetrated The Need for Surgical Robotics in Spine MIS techniques offer advantages over open surgical Robotic systems are becoming more widely adopted, procedures for patients, surge
Slide 9: Accelus Offers Key Enabling Technologies
ACCELUS OFFERS KEY ENABLING TECHNOLOGIES Addressing the Unmet Clinical Needs of Spine Surgery Multidirectional Expandable Interbody Platform Enabling Robotic Targeting and Navigation System Simple Compact Minimal Insertion Profile Affordable Improved Graft Delivery Significant Fusion Rates Providing
Slide 10: Addressing the Constraints of Minimally Invasive Spine Procedures
ADDRESSING THE CONSTRAINTS OF MINIMALLY INVASIVE SPINE PROCEDURES Simpler, safer procedures with more consistent outcomes • Reduce procedural complexity… Access Without Compromise Adaptive Geometry + Precision Robotics • Expand visualization… • Increase reproducibility… • Reduce radiation… • Address
Slide 11: Accelus Offers a Total MIS Implant Solution
ACCELUS OFFERS A TOTAL MIS IMPLANT SOLUTION Solutions to address the complete procedure Innovative Expandable Proprietary Biomaterial Robotic Targeting Interbody Platform Fixation Systems Offerings and Navigation ** * Proprietary screw Allograft comprised Economically attractive robotic Differentiat
Slide 12: Product Portfolio
A Accelus PRODUCT PORTFOLIO
Slide 13: Revolutionary Multidirectional Expandable Implant Technology
REVOLUTIONARY MULTIDIRECTIONAL EXPANDABLE IMPLANT TECHNOLOGY TM in Action What is “Adaptive Geometry”? Next-generation solution for MIS procedures Proprietary expandable cage technology, featuring multidirectional expansion of interbody devices Why Does it Matter? Minimal insertion profile with maxi
Slide 14: Game-Changing Portfolio of Spinal Implants with Adaptive Geometry
GAME-CHANGING PORTFOLIO OF SPINAL IMPLANTS WITH ADAPTIVE GEOMETRY Our Mission Solve the clinical challenges of MIS procedures through innovation and enabling technology The Problem MIS implants have chased footprint via trajectory, but results are mixed and clinical complications remain Nerve and Va
Slide 15: FlareHawk Family of Spinal Fusion Cages
Broad service offering to address MIS needs FlareHawk Family of Spinal Fusion Cages Designed For: Minimal Insertion Profile Multiplanar Expansion Improved Graft Delivery Minimizing neural retraction Wide footprint with no compromise Open architecture for continuous graft delivery * Titanium Coated 7
Slide 16: Pedicle Screw System: Allows Procedural Capture
PEDICLE SCREW SYSTEM: ALLOWS PROCEDURAL CAPTURE * Open Telescopic Screw Technology Proprietary screw technology designed to reduce current Robust implants and frustrations and complications with posterior fixation. instrumentation to Complements robotics platforms. address complex pathology MIS An a
Slide 17: Transformational Robotic Targeting and Navigation System
Optimized for daily use, with a small 30” x 30” footprint Easier to use than alternative robotic and navigation system One-third to one-fourth of the cost of alternative systems TRANSFORMATIONAL ROBOTIC TARGETING AND NAVIGATION SYSTEM ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBU
Slide 18: Robotic Targeting and Navigation System
ROBOTIC TARGETING AND NAVIGATION SYSTEM The Problem: Surgeons that need robotics are in facilities that can’t afford them Our Solution: Cost-Effective Without Attractive Surgeon Economics Rapid system positioning with quick and easy Compromise set-up and breakdown allowing surgeons to Precision navi
Slide 19: Robotic, Enabled, Minimally Invasive Targeting and Navigation System
ROBOTIC, ENABLED, MINIMALLY INVASIVE TARGETING AND NAVIGATION SYSTEM EXTRAORDINARY FEATURES… SMALLER TABLE MOUNTED SYSTEM WITH A NEARFIELD CAMERA FASTER 35% REDUCTION IN PROCEDURE TIME COMPARED TO THE COMPETITION* MORE AFFORDABLE PRICED AT A FRACTION OF THE COST COMPARED TO THE COMPETITION …WITHOUT
Slide 20: Protected Innovation, Published Clinical Data, Robust Pipeline
PROTECTED INNOVATION ROBUST PORTFOLIO PUBLISHED GLOBAL WITH INNOVATIVE CLINICAL DATA PATENT PRODUCT PIPELINE PROTECTION PEER REVIEWED, MULTI- 510(k) Pathway: 3 CENTER STUDIES ON US PATENTS FlareHawk9 FLAREHAWK 26 LineSider US APPS FlareHawk7 26 PEER REVIEWED ROBOTIC NAVIGATION 1 TiHawk STUDY INT’L P
Slide 21: Peer-Reviewed Clinical Data
PEER-REVIEWED CLINICAL DATA FlareHawk Clinical Studies Compendium of Published Peer- Reviewed FlareHawk Data • Published in International Journal of Spine Surgery (IJSS) • Three retrospective, peer-reviewed studies • Fusion rates commensurate with PLIF and TLIF procedures, minimal complications Navi
Slide 22: Product Pipeline
A Accelus PRODUCT PIPELINE
Slide 23: Journey of Innovation
JOURNEY OF INNOVATION Established History of Development With Robust Product Pipeline * * Zform Acquired technology 2015 2013 2016 2018 2019 2021 2022 & Beyond 2020 * 2-D * Toro-L Toro-Posterior & Toro-ALIF Toro-Hyperlorotic *FDA clearance pending or pipeline product under development ©2022 ACCELUS.
Slide 24: Accelus' Next Adaptive Geometry Offering
ACCELUS’ NEXT ADAPTIVE GEOMETRY OFFERING TM ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 24
Slide 25: Expandable Platform: Adaptive Geometry Reimagined
EXPANDABLE PLATFORM Adaptive Geometry Reimagined Expands wide first under minimal load then lifts with wide footprint FACILITATES ENTRANCE INTO LATERAL AND ANTERIOR MARKETS Lateral (LLIF) Posterior (PLIF / TLIF) Anterior (ALIF) 2022 2023 2023 Key Features and Benefits of Toro Platform Infinitely Ins
Slide 26: Lumbar Interbody Market by Approach
LUMBAR INTERBODY MARKET BY APPROACH MARKET FOR INTERBODY SPINAL Posterior FUSION DEVICES 58% Anterior 23%• Total U.S. Spinal Fusion market is $7.3 billion+ • ~250,000 lumbar spinal fusion procedures utilize interbody devices • Interbody devices represent a ~$2 billion market opportunity and growing…
Slide 27: Robust Pipeline to Fill Out Interbody Portfolio
LUMBAR INTERBODY MARKET BY APPROACH Posterior ROBUST PIPELINE TO FILL OUT 58% Anterior 23% INTERBODY PORTFOLIO* • Toro expands Accelus’ market opportunity Toro-Lateral ~250,000 Toro-PLIF/TLIF Toro-ALIF Total Procedures Addressed by Pipeline ADDITIONAL OPPORTUNITIES • More than 350,000 Cervical Fusio
Slide 28: Commercial Strategy
A Accelus COMMERCIAL STRATEGY
Slide 29: Attractive Business Model
ATTRACTIVE BUSINESS MODEL Enabling technology drives product pull-through Robot Placement Economically attractive option, enabling more surgeons to perform more procedures Pull-Through Screws Procedure Cross-Sale Closed robotic system Opportunities to capture drives sales of fixation additional elem
Slide 30: Established Commercial Footprint
ESTABLISHED COMMERCIAL FOOTPRINT Strong Commercial Commercialization Infrastructure Strategy ✓ Dedicated internal sales force ✓ Rapidly expand sales team ✓ Grow direct sales force in ✓ External distributor network targeted markets ✓ Growing talent pool ✓ Continue to build capital Boulder, CO sales i
Slide 31: Ambulatory Surgery Center (ASC) Market
AMBULATORY SURGERY CENTER (ASC) MARKET ENABLING TECHNOLOGIES DRIVING ASC ADOPTION GROWING ASC OPPORTUNITY • Spine procedures increasingly Enables Outpatient MIS Procedures Solves Complicated moving to ambulatory surgery Issues Simply centers • 86% of spine surgeons expect to use ASCs* • Spine surger
Slide 32: World-Class Spine Leadership
WORLD-CLASS SPINE LEADERSHIP CHRIS WALSH ALEX LUKIANOV KEVIN WILLIAMSON CEO & Co-Founder Chairman CFO ANDREW WOLF WYATT GEIST CSO CIO BRAD CLAYTON BLAKE STONE KEVIN McGANN CTO General Counsel President ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 32
Slide 33: Growth and Financials
A Accelus GROWTH AND FINANCIALS
Slide 34: Growth Opportunities
GROWTH OPPORTUNITIES International Expansion Accelerate Grow in targeted Adoption in ASCs international markets Expand Sales Reduce barriers to moving Force Regionally fusion procedures to ASCs Launch New Rapidly expand sales Product Lines Drive Pull- team to capture share Through Revenue Targeting
Slide 35: Financial Highlights
FINANCIAL HIGHLIGHTS Revenue Forecast 2021E $27.5 REVENUE 5-year Growth MILLION Expectations* 2023E $81.0 REVENUE MILLION $176M GROWING AT 2020 to 2025 $125M FORECASTED 60% CAGR $81M $48M $28M $17M Historical Non-GAAP GROSS MARGIN** 80%+ 2020 2021E 2022E 2023E 2024E 2025E *Revenue projections rounde
Slide 36: Investment Takeaways
INVESTMENT TAKEAWAYS Enabling technologies disrupting minimally invasive spine surgery Vast underserved market with opportunities to capture share Demonstrated value proposition with compelling clinical data Accelerating Robust product pipeline addressing a broader market opportunity Minimally Invas
Slide 37: Compelling Valuation
COMPELLING VALUATION EV / Revenue EV / Revenue Revenue CAGR 2022E 2023E ’21 – ’23 High Growth 11.7x 9.1x 36% Med-Tech Premium Spine 7.0x 5.8x 21% & Orthopedics Enabling Robotic 14.1x 9.9x 46% Technology 10.5x 6.2x 72% Accelus = $1.6 billion = $1.6 billion = $1.1 billion Precedent Robotic Transaction
Slide 38: Appendix
APPENDIX
Slide 39: Transaction Overview
TRANSACTION OVERVIEW Source of Funds Use of Funds Pro Forma Valuation Illustrative Pro Forma Ownership CHPM Public Shares 28% Extension Premium Accelus Funders Rollover 63% 1% Equity 8% CHPM Sponsor Shares Note: Estimated SPAC Cash in Trust assumes no redemptions. Excludes impact of 1.9 million spon
Slide 40: High Visibility to 2023 Revenue Growth
HIGH VISIBILITY TO 2023 REVENUE GROWTH Commentary $81.0 • Sales of existing products lines are Core Product Growth A anticipated to be the largest contributor to • Comprised of our existing lines including: growth, largely driven by pull-through sales • FlareHawk / TiHawk* • LineSider Fixation (pedi
Slide 41: Results of Operations
RESULTS OF OPERATIONS Year Ended Year-to-Date December 31, September 30, ($ in thousands) 2019 2020 2020 2021 Net Revenue $16,642 $16,871 $11,773 $17,901 Cost of Revenue 3,013 4,479 3,269 4,338 Gross Profit 13,629 12,392 8,504 13,563 Non-GAAP Gross Profit 1 3,849 13,689 9,519 14,399 Non-GAAP Gross M
Slide 42: Non-GAAP Financial Measures
NON-GAAP FINANCIAL MEASURES Year Ended Year-to-Date December 31, September 30, ($ in thousands) 2019 2020 2020 2021 Net Loss, as reported ($9,771) ($12,416) ($9,196) ($16,295) Adjustments: Add: Interest expense, net 332 288 215 3 ,737 Add: Amortization of intangible assets 707 707 530 1,079 Add: Dep